Clinically relevant drug interactions with tyrosine kinase inhibitors. What has to be kept in mind in medical practice?;Klinisch relevante interaktionen bei tyrosin-kinase-inhibitoren. Worauf muss in der praxis geachtet werden?

Internistische Praxis

Volumn 49, Issue 4, 2009, Pages 839-852

  Kammerer W ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Anticancer agents; Drug drug interactions; Pharmacokinetic interactions; Tyrosine kinase inhibitor

Indexed keywords

AMIODARONE; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; CYTOCHROME P450 ISOENZYME; DASATINIB; DELAVIRDINE; DILTIAZEM; ERLOTINIB; ERYTHROMYCIN; FLUCONAZOLE; FLUVOXAMINE; GEFITINIB; IMATINIB; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; NEFAZODONE; NELFINAVIR; NILOTINIB; POSACONAZOLE; PROTEIN TYROSINE KINASE INHIBITOR; SAQUINAVIR; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VORICONAZOLE;

BIOTRANSFORMATION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; ENZYME SUBSTRATE; GRAPEFRUIT JUICE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEDICAL PRACTICE; REVIEW;

EID: 70350475895     PISSN: 00209570     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Beijnen JH, Schellens H. Drug interactions in oncology. Lancet Oncol 2004; 5: 489-496.
2. Blower P, et al. Drug-drug interactions in oncology: Why are they important and can they be minimized? Crit Rev Oncol Hematol 2005; 55: 117-142.
3. Kämmerer W. Klinisch relevante pharmakokinetische Interaktionen von und mit Zytostatika. Arzneimitteltherapie 2008; 26: 51-61. (Pubitemid 351299773)
4. Lam MSH, Ignoffo RJ. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Practice 2003; 9: 45-85. (Pubitemid 37051478)
5. McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998; 45: 539-544. (Pubitemid 28270908)
6. Barth J. Molekular zielgerichtete Therapien, gibt es sie wirklich? Krankenhauspharmazie 2008; 29: 288-301.
7. Internet. Fachinformationen (www.fachinfo.de).
8. Bausch J. Teure Tyrosinkinasehemmer mit systemsprengender Wirkung. AVP 2007; 34: 94-96.
9. Reif S, et al. Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol 2002; 58: 491-494. (Pubitemid 35244924)
10. Unger M. Arzneimittelinteraktionen durch Phytopharmaka und Lebensmittel. Phytotherapie 2005; 5: 22-27.
11. Unger M. Arzneimittelneben- und Wechselwirkungen durch Phytopharmaka. Z Phytotherapie 2004; 25: 171-178. (Pubitemid 39243255)
12. Veronese ML, et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003; 43: 831-839.
13. Bhardwaj RK, et al. Piperine, a major constituent of black pepper, inhibits human glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 302: 645-650.
14. Datenbank: Micromedex Healthcare Series: Drug-dex System. Stand 30. 6. 2009.
15. Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001; 27: 221-233. (Pubitemid 32861409)
16. Scripture CD, Sparreboom A, Figg WO. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005; 6: 780. (Pubitemid 41430719)
17. Internet. Cytochrome P450 Drug Interaction Table (http://medicine. iupuLedujflockhart).
18. Brosi A, et al. Interaktionen mit P-Glykoprotein. PZ Prisma 2004; 11: 133-139.